Caption Management’s AbCellera Biologics ABCL Stock Holding History

Caption Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-40,000	Closed	-$137K	–	1609
2025 Q2	$137K	Buy	+40,000	New	+$99.6K	﹤0.01%	1298
2022 Q4	–	Sell	-350,100	Closed	-$3.46M	–	1232
2022 Q3	$3.46M	Buy	350,100 +50,100	+17%	+$550K	0.05%	466
2022 Q2	$3.19M	Buy	300,000 +100,000	+50%	+$847K	0.04%	513
2022 Q1	$1.95M	Buy	200,000 +100,000	+100%	+$947K	0.02%	765
2021 Q4	$1.43M	Sell	100,000 -63,700	-39%	-$967K	0.02%	913
2021 Q3	$3.28M	Buy	163,700 +100,000	+157%	+$1.77M	0.04%	596
2021 Q2	$1.4M	Buy	+63,700	New	+$1.76M	0.02%	798

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Caption Management's ABCL Position: Q1 2023 in Review

Caption Management sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 88,332 shares — an estimated $895K sold.

Caption Management first reported a position in ABCL in Q2 2021 and held it in 5 quarters. The position peaked at $1.01M in Q4 2021. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

Caption Management reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
Caption Management sold 88,332 AbCellera Biologics shares in Q1 2023, an estimated $895K.
Caption Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 5 quarters.
Caption Management's AbCellera Biologics position peaked at $1.01M in Q4 2021.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Caption Management's 13F filing for Q1 2023, filed 15 May 2023.